We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

By LabMedica International staff writers
Posted on 21 Sep 2014
Print article
The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials.

A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015. “In an area like cancer, where time is of the essence, the speed and accuracy that Watson offers will allow us to develop an individualized treatment plan more efficiently so we can deliver exactly the care that the patient needs,” stated Steven Alberts, MD, chair of medical oncology at Mayo Clinic. The researchers hope the increased speed also will speed new discoveries.

Clinical trials provide patients with access to new and emerging treatments; however, enrolling participants in trials is one of the more problematic areas of clinical research. Currently it is done manually, with clinical coordinators sifting through patient records and conditions, trying to correlate them with the requirements of a given study protocol. At any given time, Mayo Clinic is conducting over 8,000 human studies in addition to the 170,000 that are ongoing worldwide. Watson’s cognitive computing ability will help sift through available Mayo clinical trials and ensure that more patients are effectively and consistently matched with promising clinical trial options.

“With shorter times from initiation to completion of trials, our research teams will have the capacity for deeper, more complete investigations,” said Nicholas LaRusso, MD, a Mayo Clinic gastroenterologist and the project lead for the Mayo-IBM Watson collaboration. “Coupled with increased accuracy, we will be able to develop, refine, and improve new and better techniques in medicine at a higher level.”

This version of Watson will be expressly designed for Mayo Clinic. As it progresses in its tasks and matures through this collaboration, it will learn more about the clinical trials matching process, become even more efficient and likely more generalizable. The Watson computer also may help locate patients for hard-to-fill trials, such as those involving rare diseases.

Many clinical trials at Mayo Clinic and elsewhere are not completed due to lack of sufficient enrollment. Enrollment in general could be increased by the Watson project. In spite of well-organized efforts, even at Mayo Clinic, only 5% of patients take part in studies. In the United States, the rate is even lower, at 3%. Mayo hopes to raise clinical trial involvement to include up to 10% of its patients. Researchers say the higher participation also should improve the quality of research outcomes.

“Using Watson’s cognitive computing capabilities, Mayo Clinic can consistently offer more cutting-edge medical options to patients and conclude trials faster,” said Mike Rhodin, senior vice president, IBM Watson Group. “Ultimately, this effort will also help advance scientific discoveries into promising new forms of care that clinicians can use to treat all patients.”

To make sure that Watson has the required know-how to help with clinical trial matching, Mayo specialists are working with IBM to expand Watson’s body of knowledge to include all clinical trials at Mayo Clinic and in public databases, such as ClinicalTrials dot gov. The new Watson system is being trained to examine patient records and clinical trial criteria to determine appropriate matches for patients.

Mayo and IBM are deliberating on other applications for Watson in the future.

Related Links:

Mayo Clinic
IBM
IBM Watson Cognitive Computer


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.